ER | PR | HER2 | ||||||
---|---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | Positive | Negative | |||
Metastasis-free survival | HR | 2.2 | 2.2 | 2.6 | 2.3 | 1.2 | 2.9 | |
CTC status | 95% CI | 1.0 to 4.6 | 1.2 to 4.3 | 1.2 to 5.9 | 1.3 to 4.2 | 0.5 to 2.9 | 1.6 to 5.1 | |
P-value | 0.037 | 0.015 | 0.018 | 0.006 | 0.691 | < 0.001 | ||
HR | 2.1 | 1.1 | 1.6 | 1.5 | 1.2 | 1.6 | ||
DTC status | 95% CI | 1.2 to 3.9 | 0.5 to 2.4 | 0.7 to 3.6 | 0.8 to 2.9 | 0.5 to 3.0 | 0.9 to 2.9 | |
P-value | 0.015 | 0.902 | 0.243 | 0.179 | 0.712 | 0.103 | ||
Breast cancer specific survival | HR | 1.9 | 2.4 | 2.0 | 2.8 | 1.4 | 2.9 | |
CTC status | 95% CI | 0.7 to 4.8 | 1.2 to 4.6 | 0.7 to 5.6 | 1.5 to 5.2 | 0.5 to 3.4 | 1.5 to 5.5 | |
P-value | 0.180 | 0.01 | 0.200 | 0.001 | 0.504 | 0.001 | ||
HR | 2.9 | 1.1 | 1.4 | 2.0 | 1.6 | 1.7 | ||
DTC status | 95% CI | 1.4 to 5.7 | 0.5 to 2.5 | 0.5 to 3.9 | 1.1 to 3.8 | 0.7 to 4.0 | 0.9 to 3.3 | |
P-value | 0.003 | 0.832 | 0.560 | 0.025 | 0.268 | 0.098 |